JP2009541236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541236A5 JP2009541236A5 JP2009515748A JP2009515748A JP2009541236A5 JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5 JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009515748 A JP2009515748 A JP 2009515748A JP 2009541236 A5 JP2009541236 A5 JP 2009541236A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- moiety
- group
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- -1 (phenyl) ethyl Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 10
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 claims 7
- 239000013603 viral vector Substances 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 229960005486 vaccine Drugs 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 241000700618 Vaccinia virus Species 0.000 claims 3
- 230000002238 attenuated effect Effects 0.000 claims 3
- 230000002708 enhancing effect Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical class C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 0 CCCCCCCCC[C@](CCC(*C(C1C2*C([Ru])=**C1)NCC)C2(CC)C1CCCCCC1)*(C)(C)C Chemical compound CCCCCCCCC[C@](CCC(*C(C1C2*C([Ru])=**C1)NCC)C2(CC)C1CCCCCC1)*(C)(C)C 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06360028 | 2006-06-20 | ||
| US85296406P | 2006-10-20 | 2006-10-20 | |
| PCT/EP2007/005303 WO2007147529A2 (en) | 2006-06-20 | 2007-06-15 | Recombinant viral vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541236A JP2009541236A (ja) | 2009-11-26 |
| JP2009541236A5 true JP2009541236A5 (OSRAM) | 2010-07-29 |
Family
ID=38657260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515748A Ceased JP2009541236A (ja) | 2006-06-20 | 2007-06-15 | 組換えウイルスワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100129403A1 (OSRAM) |
| EP (1) | EP2029169A2 (OSRAM) |
| JP (1) | JP2009541236A (OSRAM) |
| KR (1) | KR101141333B1 (OSRAM) |
| CN (1) | CN101472610A (OSRAM) |
| AU (1) | AU2007263281B2 (OSRAM) |
| BR (1) | BRPI0713711A2 (OSRAM) |
| CA (1) | CA2656266C (OSRAM) |
| CR (1) | CR10571A (OSRAM) |
| IL (1) | IL195683A0 (OSRAM) |
| MA (1) | MA30581B1 (OSRAM) |
| MX (1) | MX2008016036A (OSRAM) |
| NO (1) | NO20090194L (OSRAM) |
| RU (1) | RU2453335C2 (OSRAM) |
| WO (1) | WO2007147529A2 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012001592A (es) | 2009-08-07 | 2012-05-22 | Transgene Sa | Composicion para el tratamiento de la infección del virus de la hepatitis b. |
| US9216213B2 (en) * | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TW201321016A (zh) | 2011-09-29 | 2013-06-01 | Transgene Sa | 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二） |
| TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一） |
| EP2872172B1 (en) | 2012-07-10 | 2018-11-14 | Transgene SA | Mycobacterial antigen vaccine |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| CA2936131A1 (en) | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| DK3562946T3 (da) | 2016-12-28 | 2022-01-31 | Transgene Sa | Oncolytiske virusser og terapeutiske molekyler |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| CA3151667A1 (en) | 2019-08-29 | 2021-03-04 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| CA3189238A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| CA3260559A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant D protein and a component of TNFSF |
| JP2025528219A (ja) | 2022-08-18 | 2025-08-26 | トランジェーヌ | キメラポックスウイルス |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| ES2094141T3 (es) | 1989-02-27 | 1997-01-16 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales. |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| PL354997A1 (en) | 1999-09-25 | 2004-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1478371A4 (en) | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS |
| ATE491471T1 (de) * | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
| WO2005018574A2 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
| US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
-
2007
- 2007-06-15 AU AU2007263281A patent/AU2007263281B2/en not_active Ceased
- 2007-06-15 CN CNA2007800232312A patent/CN101472610A/zh active Pending
- 2007-06-15 CA CA2656266A patent/CA2656266C/en not_active Expired - Fee Related
- 2007-06-15 BR BRPI0713711-7A patent/BRPI0713711A2/pt not_active IP Right Cessation
- 2007-06-15 EP EP07764675A patent/EP2029169A2/en not_active Withdrawn
- 2007-06-15 US US12/306,227 patent/US20100129403A1/en not_active Abandoned
- 2007-06-15 JP JP2009515748A patent/JP2009541236A/ja not_active Ceased
- 2007-06-15 MX MX2008016036A patent/MX2008016036A/es active IP Right Grant
- 2007-06-15 RU RU2009101387/15A patent/RU2453335C2/ru not_active IP Right Cessation
- 2007-06-15 WO PCT/EP2007/005303 patent/WO2007147529A2/en not_active Ceased
- 2007-06-15 KR KR1020087030973A patent/KR101141333B1/ko not_active Expired - Fee Related
-
2008
- 2008-12-03 IL IL195683A patent/IL195683A0/en unknown
-
2009
- 2009-01-09 MA MA31557A patent/MA30581B1/fr unknown
- 2009-01-13 NO NO20090194A patent/NO20090194L/no not_active Application Discontinuation
- 2009-01-16 CR CR10571A patent/CR10571A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541236A5 (OSRAM) | ||
| CA2656266A1 (en) | Recombinant viral vaccine | |
| Patel et al. | Novel drugs targeting Toll-like receptors for antiviral therapy | |
| RU2018116351A (ru) | Пиримидиновое соединение | |
| JP2007511546A5 (OSRAM) | ||
| JP2011529918A5 (OSRAM) | ||
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| NL300899I2 (nl) | Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit en Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie B01 eiwit | |
| JP2012528892A5 (OSRAM) | ||
| JP2012092103A5 (OSRAM) | ||
| JP2002541233A5 (OSRAM) | ||
| JP2008501000A5 (OSRAM) | ||
| JP2014521688A5 (OSRAM) | ||
| JP2006524669A5 (OSRAM) | ||
| JP2020500916A5 (OSRAM) | ||
| JP2016503029A5 (OSRAM) | ||
| JP2015512946A5 (OSRAM) | ||
| JP2013507423A5 (OSRAM) | ||
| JP2014515406A5 (OSRAM) | ||
| KR20170106453A (ko) | 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용 | |
| JP2009523777A5 (OSRAM) | ||
| JP2014532716A5 (OSRAM) | ||
| JP2012532883A5 (OSRAM) | ||
| JP2014028916A5 (OSRAM) | ||
| CN1950376A (zh) | 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 |